An overview of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors associated with HIV therapy

International Journal of Pharmacology

Volumn 2, Issue 1, 2006, Pages 152-162

  Fokunang, C N ^a   Hitchcock, J ^a   Spence, F ^a   Tembe Fokunang, E A ^a   Burkhardt, J ^a   Levy, L ^a   George, C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

HIV therapy; Mitochondrial toxicity; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ADEFOVIR; ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; CELL NUCLEUS DNA; DIDANOSINE; DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE GAMMA; ELVUCITABINE; GROWTH FACTOR; LAMIVUDINE; MITOCHONDRIAL DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEMOGLOBIN; RIBAVIRIN; RIBOSOME RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRANSFER RNA; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BONE NECROSIS; CARDIOMYOPATHY; CLINICAL TRIAL; DNA SYNTHESIS; DRUG ACTIVATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TRANSPORT; DRUG WITHDRAWAL; ENZYME INHIBITION; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER FAILURE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL GENETICS; MITOCHONDRIAL TOXICITY; MYOPATHY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VIRUS DNA CELL DNA INTERACTION;

EID: 33644538255     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2006.152.162     Document Type: Review

References (113)

1. Lewis, W., J.F. Simpson and R.R. Meyer, 1994. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circulation Res., 74: 344-348.
2. Moyle, G.J., 2004. Mitochondria toxicity: Myths and facts. J. HIV Ther., 9: 45-47.
3. Moyle, G.J. and M. Sadler, 1998. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Safety, 19: 481-494.
4. Lopez, S., O. Miro, E. Martinez and E. Pedrol, 2004. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir. Ther., 9: 47-55.
5. Lecrenier, N. and F. Foury, 2000. New features of mitochondrial DNA replication system in yeast and man. Gene., 246: 37-48.
6. 2 cells as a model for in vitro studies on mitochondrial toxicity of antiviral drugs: which correlation with the patients? J. Biol. Regul. Homeost. Agents, 17: 166-71.
7. White, A.J., 2001. Mitochondria toxicity and HIV therapy. Sex Trans. Inform., 77: 158-173.
8. Lee, H., J. Hanes and K.A. Johnson, 2003. Toxicity of nucleoside analogues used to treat AIDs and the selectivity of mitochondrial DNA polymerase. Biochem., 42: 14711-9.
9. Jacotot, E., K.F. Ferri and C. El Hamel, et al., 2001. Control of mitochondrial membrane permeabilisation by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. J. Exp. Med., 193: 509-519.
10. Lewis, W., 2003. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions. Antivir. Res., 58: 189-197.
11. Ogedegbe, A.E.O., D.L.Thomas and A.M. Diehl, 2003. Hyperlactataemia syndrome associated with HIV therapy. The Lancet, 3: 329-337.
12. Leonard, J.V. and A.H.V. Schapira, 2000. Mitochondrial respiratory chain disorders I: Mitochondrial DNA defects. Lancet, 355: 299-304.
13. Mandavilli, B.S., J. Santos and B. Van Houten, 2002. Mitochondrial DNA repair and aging. Mutation. Res., 509: 127-151.
14. Rossi, L., S. Serafini and G.F. Schiavano, 1999. Metabolism, mitochondrial uptake and toxicity of 2′, 3′-dideoxycytidine. Biochem. J., 344: 915-20.
15. Ballinger, S.W., B. Van Houten and C.A. Coklin, 1999. Hydrogen peroxide causes significant mitochondrial DNA damage in human RPE cells. Exp. Eye Res., 68: 765-772.
16. Fleischer, R., D. Boxwell and K.E. Sherman, 2004. Nucleoside analogues and mitochondrial toxicity. Clin. Infect. Dis., 15, 38: 79-80.
17. Benbrik, E., P. Chariot and S. Bonavaud, et al., 1997. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci., 149: 19-25.
18. Bishop, J.B., Y. Tani, K. Witt, J.A. Johnson and S. Peddada, 2004. Mitochondria damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol. Sci., 81: 512-517.
19. Taanman, J.W., 1999. The mitochondrial genome: Structure, transcription, translation and replication. Biochim. Biophys. Acta, 1410: 103-123.
20. Adkins, J.C., D.H. Peters and D. Faulds, 1997. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs, 53: 1054-80.
21. Cherrington, J.M., S.J.W. Allen and N. Bischofberger, 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases alpha, beta and gamma. Antiviral Chem. Chemother., 6: 217-221.
22. Antoniades, C., C. Macdonald, A. Knisely, C. Taylor and S. Norris, 2004. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl., 10: 699-702.
23. Ropp, P.A. and W.C. Copeland, 1996. Cloning and characterization of the human mitochondrial DNA polymerase, DNA polymerase gamma. Genomics, 36: 449-58
24. Davis, A.F., P.A. Ropp and D.A. Clayton, 1996. Mitochondrial DNA polymerase gamma is expressed and translated in the absence of mitochondrial DNA maintenance and replication. Nucleic Acids Res., 24: 2753-9.
25. Glesby, M.J., 2002. Overview of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. Perspect Intl. AIDS. Soc. USA., 10: 42-46.
26. Rasmussen, L.J. and K.K. Singh, 1998. Genetic Integrity of the Mitochondrial Genome. In: Singh, K.K., (Ed.) Mitochondrial DNA mutations in aging, disease and cancer. Berlin, New York: Springer-Verlag and RG Landes, pp: 115-27.
27. De la Asuncion, J.G., N. del Olmo, M.L. Sastre, A. Millan and A. Pellin,. 1998. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J. Clin. Invest., 102: 4-9.
28. Carr, A., J. Miller amd M. Law, 2000. A syndrome of lipoatrophy lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS., 14: F25-32.
29. Brinkman, K., J.A. Smeitink and J.A. Romijn et al., 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet., 354: 1112-5.
30. Chiappini, F., E. Teiccher, R. Saffroy and P. Pham,. 2004. Prospoective evaluation of blood concentration of mitochondrial DNA as marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab. Invest., 84: 908-14.
31. Wright, G.E. and N.C. Brown, 1990. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmacol. Ther., 47: 447-497.
32. Shaw-Reid, C.A., B. Feuston and V. Munshi, et al., 2005. Dissecting the effects of DNA polymerase and Ribonuclease H inhibitor Combinations on HIV-1 Reverse-Transcriptase Activities. Biochem., 44: 1595-1606.
33. Srivastava, D.K., C.L. Tendler and D. Milani,. 2001.The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme β-polymerase. AIDS., 15: 433-40.
34. Cheng, Y.C., W.Y. Gao and C.H. Chen, 1990. DNA polymerases versus HIV reverse transcriptase in AIDS therapy. Ann. NY. Acad Sci., 616: 217-23.
35. Lori, F., L.M. Kelly and J. Lisziewicz, 2004. Safety of hydroxyurea in the treatment of HIV infection. Exp. Opin. Drug. Saf., 3: 279-288.
36. Luster, M.I., D.R. Germolec and K.L.J. White, et al., 1989. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: In vitro toxicity to precursor cells and microstromal environment. Toxicol Applied Pharmacol., 101: 328-339.
37. Ter Hofstede, H.J., H.L. Willems and P.P. Koopmans, 2004. Serum L-lactate and pyruvate in HIV-infected patients and with and without presumed nRTI-related adverse events compared to healthy volunteers. J. Clin. Virol., 29: 44-50.
38. Cui, L., L. Locatelli and M.Y. Xie, et al., 1997. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J. Pharmacol. Exp. Ther., 280: 1228-34.
39. Kakuda, T.N., 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther., 22: 685-708.
40. Martin, J.L., C.E. Brown and N. Matthews-Davis, 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother., 38: 2743-9.
41. Lipshultz, S.E., E.J. Orav and S.P. Sanders et al., 1992. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N. Engl. J. Med., 327: 1260-5.
42. Lipshultz, S.E., 2001. Absence of cardiac toxicity of zidovudine in infants-reply. N. Engl. J. Med., 344: 458.
43. Tornevik, Y., B. Ullman and J. Balzarini et al., 1995. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol., 49: 829-837.
44. Lipshultz, S.E., 1998. Dilated cardiomyopathy in HIV-infected patients. N. Engl. J. Med., 339: 1153-5.
45. Bridges, E.G., Z. Jiang and Y.C. Cheng, 1999. Characterization of a dCTP transport activity reconstituted from human mitochondria. J. Biol. Chem., 274: 4620-5.
46. Dutschman, G.E., E.G. Bridges and S.H. Liu, 1998. Metabolism of 2′, 3′-dideoxy-2′,3′-didehydro-β-L(-)- 5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother., 42: 1799804
47. Dalakas, M.C., I. Illa and G.H. Pezeshkpour et al., 1990. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med., 322: 1098-105.
48. Brinkman, K., H.J. Ter Hofstede and D.M. Burger, 1998. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS., 12: 1735-1744.
49. Lewis, W. and M.C. Dalakas, 1995. Mitochondria] toxicity of antiviral drugs. Nature Med., 1: 417-22.
50. Freiman, J.P., K.E. Helfert and M.R. Hamrell, 1993. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS., 7: 379-85.
51. Moses, A., J. Nelson and J.G.C. Bagby, 1998. Review article: the influence of human immunodeficiency virus-1 on hematopoiesis. Blood, 91: 1479-1495.
52. Wilde, M.I. and H.D. Langtry, 1993. Zidovudine: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs., 46: 515-578.
53. Walker, U.A., M. Bickel and S.I. Volksbeck, et al., 2000. Decrease of mitochondria DNA content in adipose tissie of HIV-1 infected patients treated with nRTIs. Antiviral Ther., 5: 5-6.
54. Hermans, J.S. and P.J. Easterbrook, 2001. The metabolic toxicities of antiretroviral therapy. Intl. J. STD AIDS., 12: 555-62.
55. Moquattash, S., J.D, Lutton and G. Rosenthal, 1997. Effect of blood substitute, recombinant hemoglobin, on in vivo hematopoietic recovery from AZT toxicity. Acta Haematol., 98: 76-82.
56. Henry, D.H., G.N. Beall and C.A. Benson, et al., 1992. Recombinant human erythropoietin in the treatment of anaemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials [see comments]. Ann. Intl. Med., 117: 739-48.
57. Chariot, P. and R. Gherardi, 1995. Myopathy and HIV infection. Curr. Opin. Rheumatol., 7: 497-502.
58. Simpson, D.M., K.A. Citak and E. Godfrey, 1993. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology, 43: 971-6.
59. Simpson, D.M., D.A. Katzenstein and M.D. Hughes, 1998. Neuromuscular function in HIV infection: Analysis of a placebo-controlled combination antiretroviral trial. AIDS., 12: 2425-32.
60. Masanes, F., A. Barrientos and M. Cebrian, et al., 1998. Clinical, histological and molecular reversibility of zidovudine myopathy. J. Neurol. Sci., 159: 226-8.
61. Lewis, W., I.L. Grupp and G. Grupp, et al., 2000. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab. Invest., 80: 187-97.
62. Barbaro, G., G. Di Lorenzo and B Grisorio. 1998. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N. Engl. J. Med., 339: 1093-1099.
63. DiMauro, S. and M. Hirano, 1998. Mitochondria and heart disease. Curr. Opin. Cardiol., 13: 190-7.
64. Yunis, N.A. and V.E. Stone, 1998. Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. J. Acquir. Immune. Defic. Syndr., 18: 145-54.
65. Herskowitz, A., S.B. Willoughby and K.L. Baughman et al., 1992. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases. Ann. Intl. Med., 116: 311-3.
66. Wulff, E.A., A.K. Wang and D.M. Simpson, 2000. HIV-associated peripheral neuropathy. Drugs., 59: 1251-60.
67. Lonergan, J.T., R.E. Barber and W.C. Mathews, 2003. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS., 17: 2495-9.
68. Carr, A., J. Miller, J.A. Eisman and D.A. Cooper, 2001. Osteopenia in HIV-infected men: Association with asymptomatic lactic academia and lower weight pre-antiretroviral therapy. AIDS., 13: 703-9.
69. Monier, P.L. and R. Wilcox, 2004. Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1 infected adults. Am. J. Med. Sci., 328: 48-56.
70. John, M., D. Nolan and S.A. Mallal, 2001. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther., 6: 9-20.
71. Manfredi, R., L. Calza and F. Chiodo, 2002. A life-long antiretroviral treatment of congenital HIV disease, associated with a mixed fat redistribution syndrome and osteopenia already occurred during pre-pubertal age. Intl. J. STD AIDS., 13: 504-7.
72. Springer, S.A. and F.L. Altice, 2003. Human immunodeficiencyvirus infection with granulocytic ehrlichiosis complicated by symptomatic lactic acidosis. Clin. Infect. Dis., 36: 162-4.
73. Gerard, Y., L. Maulin and Y. Yazdanpanah, 2000. Symptomatic hyperlactatemia: An emerging complication of antiretroviral therapy. AIDS., 14: 2723-30.
74. Sheng, W.H., S.M. Hsieh, S.C. Lee and M.Y. Cheng, 2004. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan. Intl. J. STD AIDS., 15: 249-53.
75. Moreno, A., C. Quereda, L. Moreno and M.J. Perez-Elias et al., 2004. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinnfected patients receiving ribavirin. Antivir. Ther., 9: 133-8.
76. Gervasoni, C., A.L. Ridolfo and U. Trifiro, 1999. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS., 13: 465-71.
77. Harris, M., A. Tesiorowski and K. Chan et al., 2000. Lactic acidosis complicating antiretroviral therapy: Frequency and correlates. Antiviral Ther., 5: 31.
78. Saint-Marc, T. and J.L. Touraine, 1999. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS., 13: 2188-9.
79. Bogner, J.R., G.M. Michl and W. Neuhofer, 2000. No difference in lipodystrophy incidence in stavudine versus zidovudine nucleoside backbone: Blinded evaluation in a cohort on first line HAART. Antiviral Ther., 5: 55.
80. Villarroya, F., P. Domingo and M. Giralt, 2005. Lipodystrophy associated with highly active antiretroviral therapy for HIV infection: The adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol. Sci., 26: 88-93.
81. Kakuda, T.N., R.C. Brundage and P.L. Anderson,. 1999. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS., 13: 2311-2.
82. Clark, A., 2000. Improvement of facial lipoatrophy after substitution of stavudine. Antiviral Ther., 5: 73-74.
83. Nolan, D. and F. Christiansen, 2003. 4th International workshop on adverse drug reactions and lipodystrophy HIV. San Diego, California, USA. 22-25 September 2002. Exp. Opin. Drug. Saf., 2: 703-9.
84. Brinkman, K. and H.J. Ter Hofstede, 1999. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options. AIDS Rev., 1: 140-6.
85. Law, M., S. Emery and M. French et al., 2000. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy. Antiviral Ther., 5: 18.
86. Moyle, G.J. and A. Carr, 2002. HIV-associated lipodystrophy, metabolic complications and antiretroviral toxicities. HIV Clin. Trials, 3: 89-98.
87. Paice, J.A., S. Shott and F. Oldenburg, 2000. Efficacy of a vibratory stimulus for the relief of HIV-associated neuropathic pain. Pain, 84: 291-6.
88. Ho, H.T. and M.J. Hitchcock, 1989. Cellular pharmacology of 2′, 3′-dideoxy-2′, 3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother., 33: 844-9.
89. Heath, K.V., J.S. Montaner, G. Bondy and J. Singer, et al., 2003. Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection. Curr. Drug. Targets, 4: 13-22.
90. Smith, K.Y., 2002. Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J. Infect. Dis., 185: 123-7.
91. Hermans, P., W. Rozenbaum and A. Jou, 1996. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS., 10: 1627-33
92. Foli, A., F, Benvenuto and G. Piccinini, 2000. A convenient assay for in vitro evaluation of mitochondrial toxicity of antiretroviral drugs. Antiviral Ther., 5: 34-5.
93. Genne, D., P. Sudre and D. Anwar et al., 2000. Causes of macrocytosis in HIV-infected patients not treated with zidovudine. J. Infect., 40: 160-3.
94. Dolce, V., G. Fiermonte and M.J. Runswick et al., 2001. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc. Natl. Acad Sci. USA., 98: 2284-8.
95. Montessori, V., N. Press, M. Harris, L. Akagi and J.S. Montaner, 2004. Adverse effects of antiretroviral therapy for HIV infection. CMA J., 170: 229-38.
96. Simpson, D.M. and M. Tagliati, 1995. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J. Acquir. Immune. Defic. Syndr., 9: 153-61.
97. Khan, J., S. Lagakos and M. Wulfsohn et al., 1999. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA., 282: 2305-12.
98. Paulik, M., M. Lancaster and D. Croom, 2000. Antioxidants rescue nRTI-induce metabolic changes in AKR/J mice. Antiviral Ther., 5: 6-7.
99. Moore, R.D., W.E. Wong and J.C. Keruly, 2000. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS., 14: 273-8.
100. Mallal, S.A., M. John and C.B. Moore et al., 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS., 14: 1309-16.
101. Niaudet, P., 1998. Mitochondria disorders and the kidney. Arch. Dis. Child, 78: 383-393.
102. Crowther, M.A., W. Callaghan and A.B. Hodsman, 1993. Dideoxyinosine-associated nephrotoxicity (letter). AIDS., 7: 131-2.
103. Blasi, E., B. Colombari C.F. Orsi and M. Pinti et al., 2004. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Crytococcus neoform FEMS Immunol. Med. Microbiol., 42: 187-195.
104. Leonard, J.V. and A.H.V. Schapira, 2000. Mitochondrial respiratory chain disorders. II: Neurodegenerative disorders and nuclear gene defects. Lancet, 355: 389-94.
105. Brinkman, K. and T.N. Kakuda, 2000. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term antiretroviral therapy? Curr. Opin. Infect. Dis., 19: 5-11.
106. Moon, S.K., L.J. Thompson, N. Madamanchi and J. Ballinger et al., 2001. Aging, oxidative stress and proliferative capacity in cultured mouse aortic smooth muscle cells. Am. J. Physiol. Heart Cir. Physiol., 280: 2779-2788.
107. Morris, A.A.M., S. Baudouin and M.H. Snow, 2001. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS., 15: 140-1.
108. Dassopoulos, T. and E.D. Ehrenpreis, 1999. Acute pancreatitis in human immunodeficiency virus-infected patients: A review. Am. J. Med., 107: 78-84.
109. John, M., C. Moore and J.R. James, et al., 2001. Chronic hyperlactaemia in HIV-infected patients taking antiretroviral therapy. AIDS., 15: 717-23.
110. Leonard, J.V. and A.H.V. Schapira, 2000. Mitochondrial respiratory chain disorders. II: Neurodegenerative disorders and nuclear gene defects. Lancet, 355: 389-94.
111. Shaer, A.J. and A. Rastegar, 2000. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome a case report and review of the literature. Am. J. Nephrol., 20: 332-8.
112. Shoffner, J.M. and D.C. Wallace, 1992. Mitochondrial genetics: Principles and practice. Am. J. Human Genet., 51: 1179-86.
113. Simpson, D.M., P. Slasor and U. Dafni et al., 1997. Analysis of myopathy in a placebo-controlled zidovudine trial. Muscle Nerve, 20: 382-5.